ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan
July 08, 2024 08:00 ET
|
Oryzon Genomics, S.A.
MADRID and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
June 28, 2024 09:28 ET
|
Oryzon Genomics, S.A.
All resolutions were approvedAdditional resolution to increase capital for up to 100 million euros approved42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 ...
ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference
June 26, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Selected for oral presentationConference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015,...
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
June 14, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activityA third cohort is ongoing following FDA’s OPTIMUS...
ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology
June 03, 2024 08:00 ET
|
Oryzon Genomics, S.A.
The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML)The combination showed substantial antileukemic...
ORYZON to Provide Corporate Progress Updates at Several Events in June
May 30, 2024 08:00 ET
|
Oryzon Genomics, S.A.
BIO International Convention 2024European Hematology Association (EHA) 2024 European Network to Cure ALS (ENCALS) 2024 MADRID and CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Oryzon...
ORYZON Selected as Associated Partner in the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
May 29, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia, and SpainOryzon to validate epigenetic agents by applying a personalized medicine...
ORYZON to Provide Corporate Progress Updates at Several Events in May
May 09, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Bio-Equity Europe 2024Asebio Investor Day 2024RSC Hot Topics: Covalent Drug DiscoveryForo Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024
May 06, 2024 12:03 ET
|
Oryzon Genomics, S.A.
Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans...
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
April 22, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Has received “Intention to Grant” from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon...